CO2020000328A2 - Formulaciones a largo plazo - Google Patents

Formulaciones a largo plazo

Info

Publication number
CO2020000328A2
CO2020000328A2 CONC2020/0000328A CO2020000328A CO2020000328A2 CO 2020000328 A2 CO2020000328 A2 CO 2020000328A2 CO 2020000328 A CO2020000328 A CO 2020000328A CO 2020000328 A2 CO2020000328 A2 CO 2020000328A2
Authority
CO
Colombia
Prior art keywords
long
pharmaceutical compositions
term formulations
formulations
term
Prior art date
Application number
CONC2020/0000328A
Other languages
English (en)
Inventor
Koenraad Jozef Lodewijk Marcel Andries
Maristella Bernini
Esther Dina Guido Basstanie
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CO2020000328A2 publication Critical patent/CO2020000328A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Esta invención se refiere a composiciones farmacéuticas para la administración por vía intramuscular o inyección subcutánea, que comprende micro o nanopartículas del compuesto bedaquilina anti-TB, suspendido en un vehículo acuoso farmacéuticamente aceptable, y al uso de tales composiciones farmacéuticas en el tratamiento y profilaxis de una infección por micobacterias patógenas.
CONC2020/0000328A 2017-07-14 2020-01-14 Formulaciones a largo plazo CO2020000328A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17181354 2017-07-14
EP18167463 2018-04-16
PCT/EP2018/069066 WO2019012100A1 (en) 2017-07-14 2018-07-13 EXTENDED ACTION FORMULATIONS

Publications (1)

Publication Number Publication Date
CO2020000328A2 true CO2020000328A2 (es) 2020-01-31

Family

ID=62874924

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2020/0000328A CO2020000328A2 (es) 2017-07-14 2020-01-14 Formulaciones a largo plazo

Country Status (27)

Country Link
US (2) US11141384B2 (es)
EP (3) EP3651736B1 (es)
JP (3) JP7102500B2 (es)
KR (1) KR20200028964A (es)
CN (2) CN115252548A (es)
AU (1) AU2018298855A1 (es)
BR (1) BR112020000687A2 (es)
CA (1) CA3069069A1 (es)
CO (1) CO2020000328A2 (es)
CY (1) CY1124782T1 (es)
DK (2) DK3943070T3 (es)
ES (1) ES2891976T3 (es)
FI (1) FI3943070T3 (es)
HR (2) HRP20240058T1 (es)
HU (2) HUE064651T2 (es)
JO (1) JOP20200004B1 (es)
LT (2) LT3943070T (es)
MD (1) MD3651736T2 (es)
PE (1) PE20200336A1 (es)
PH (1) PH12020500076A1 (es)
PL (2) PL3943070T3 (es)
RS (2) RS62362B1 (es)
SA (1) SA520410975B1 (es)
SI (2) SI3651736T1 (es)
UA (1) UA126403C2 (es)
WO (1) WO2019012100A1 (es)
ZA (1) ZA202000215B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220023282A1 (en) * 2018-12-13 2022-01-27 Mannkind Corporation Compositions of Bedaquiline, Combinations Comprising Them, Processes for Their Preparation, Uses and Methods of Treatment Comprising Them
US20230355606A1 (en) 2020-07-09 2023-11-09 Janssen Pharmaceutica Nv Long-acting formulations
CN115867259A (zh) 2020-07-09 2023-03-28 詹森药业有限公司 长效配制品
WO2022008644A1 (en) 2020-07-09 2022-01-13 Janssen Pharmaceutica Nv Long-acting formulations
US11793808B2 (en) 2021-02-22 2023-10-24 Mannkind Corp. Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them
WO2024068699A1 (en) 2022-09-28 2024-04-04 Janssen Pharmaceutica Nv Long-acting formulations
WO2024068693A1 (en) 2022-09-28 2024-04-04 Janssen Pharmaceutica Nv Long-acting formulations

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
EP1527050B1 (en) 2002-07-25 2010-04-07 Janssen Pharmaceutica N.V. Quinoline derivatives and their use as mycobacterial inhibitors
EE05394B1 (et) 2004-12-24 2011-04-15 Janssen Pharmaceutica N.V. Kinoliinihendid kasutamiseks latentse tuberkuloosi ravis
EP1888604B1 (en) 2005-05-25 2012-03-14 Janssen Pharmaceutica NV Process for preparing (alpha s, beta r)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol
BRPI0713334B1 (pt) 2006-06-23 2024-02-20 Janssen Sciences Ireland Uc Uso de 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]-amino]-2-pirimidinil]-amino]-benzonitrila para tratar ou prevenir infecção por HIV
LT2696848T (lt) 2011-04-15 2020-09-10 Janssen Pharmaceutica N.V. Liofilizuotos vaisto nanosuspensijos
ES2948805T3 (es) * 2015-01-27 2023-09-19 Janssen Pharmaceutica Nv Composiciones dispersables
US10653679B2 (en) * 2015-05-04 2020-05-19 Board Of Trustees Of Michigan State University Compositions and methods for inhibiting bacterial growth
KR102106318B1 (ko) * 2015-10-20 2020-05-06 쯔지앙 하이썬 파머슈티컬 컴퍼니, 리미티드 베다퀼린 푸마레이트의 결정형 및 그의 제조방법
EP3634583A4 (en) 2017-06-06 2021-03-03 Merck Sharp & Dohme Corp. LONG-ACTION IMPLANT FOR THE TREATMENT OF INFECTIOUS DISEASES

Also Published As

Publication number Publication date
PH12020500076A1 (en) 2020-11-09
CY1124782T1 (el) 2022-11-25
SI3943070T1 (sl) 2024-03-29
JP7441276B2 (ja) 2024-02-29
JOP20200004B1 (ar) 2023-09-17
FI3943070T3 (fi) 2024-01-24
AU2018298855A1 (en) 2020-01-16
CN110869004A (zh) 2020-03-06
US20220047522A1 (en) 2022-02-17
CN115252548A (zh) 2022-11-01
PL3651736T3 (pl) 2021-12-20
DK3651736T3 (da) 2021-09-27
CN110869004B (zh) 2022-06-14
PE20200336A1 (es) 2020-02-14
JOP20200004A1 (ar) 2020-01-14
ZA202000215B (en) 2021-07-28
PL3943070T3 (pl) 2024-05-06
EP3943070B1 (en) 2023-11-22
BR112020000687A2 (pt) 2020-07-14
WO2019012100A1 (en) 2019-01-17
SA520410975B1 (ar) 2022-07-16
JP2024038043A (ja) 2024-03-19
EP3651736B1 (en) 2021-06-23
HUE064651T2 (hu) 2024-04-28
JP2022130709A (ja) 2022-09-06
KR20200028964A (ko) 2020-03-17
HUE055762T2 (hu) 2021-12-28
CA3069069A1 (en) 2019-01-17
LT3651736T (lt) 2021-10-11
MD3651736T2 (ro) 2021-12-31
JP2020526538A (ja) 2020-08-31
DK3943070T3 (da) 2024-01-22
EP3651736A1 (en) 2020-05-20
RS62362B1 (sr) 2021-10-29
SI3651736T1 (sl) 2021-11-30
US20210085620A1 (en) 2021-03-25
RS65207B1 (sr) 2024-03-29
HRP20211450T1 (hr) 2022-01-07
JP7102500B2 (ja) 2022-07-19
HRP20240058T1 (hr) 2024-03-29
US11141384B2 (en) 2021-10-12
EP4356968A2 (en) 2024-04-24
LT3943070T (lt) 2024-02-12
EP3943070A1 (en) 2022-01-26
UA126403C2 (uk) 2022-09-28
ES2891976T3 (es) 2022-02-01

Similar Documents

Publication Publication Date Title
CO2020000328A2 (es) Formulaciones a largo plazo
SV2018005629A (es) Compuestos antivirales de fosfodiamida de ester de beta-aminoacido
CL2017000309A1 (es) Indoles para su uso en la infección por el virus de la gripe
CL2018000684A1 (es) Moduladores de la proteína de núcleo de la hepatitis b.
CL2017001191A1 (es) Compuestos derivados de carbamoilpiridona policíclicos; composición farmacéutica que los comprende; y su uso para el tratamiento de una infección de vih en un humano que tiene o se encuentra en riesgo de tener la infección.
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
CL2015001864A1 (es) Compuestos derivados de espiropirido[1,2-a]pirazina sustituidos, como inhibidores de la integrasa del vih; composicion farmaceutica que los comprende; y su uso para la profilaxis o el tratamiento de una infeccion por vih.
CL2018001199A1 (es) Composiciones terapéuticas para el tratamiento del virus de inmunodeficiencia humana
CL2016000698A1 (es) Derivados de quinolizina sustituidos útiles como inhibidores de integrasa del vih
ECSP18061667A (es) Pirimidinas sustituidas con arilo para su uso en la infección por virus influenza
UY30431A1 (es) Suspensiones acuosas de tmc278
CL2017000533A1 (es) Pirrolopirimidinas para uso en la infección por el virus de la gripe
UY36465A (es) Compuestos policíclicos de carbamoilpiridona y su uso farmacéutico
CL2016000008A1 (es) Tratamiento de lesiones inflamatorias de rosacea con ivermectina.
CO2019001044A2 (es) Composición de cannabis
UY37168A (es) Profármacos de principios activos citotóxicos con grupos enzimáticamente escindibles
CO2023001340A2 (es) Formulaciones a largo plazo
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico
GT201700124A (es) Formulación de relación fija de insulina glargina/lixisenatida
CO2017011284A2 (es) Combinaciones antihelmínticas y métodos de uso de ellas
AR094707A1 (es) Compuesto de quinazolin-4-amina, composición farmacéutica que lo comprende y su uso para el tratamiento de una enfermedad mediada por la quinasa rip2
CL2016002879A1 (es) Composiciones farmacéuticas para tratar enfermedades infecciosas
UY37488A (es) Novedosas formulaciones de compuestos de beta-lactama sustituidos con amidina sobre la base de ciclodextrinas modificadas y agentes acidificantes, su preparación y uso como composiciones farmacéuticas antimicrobianas
UY36217A (es) Compuestos piridona sustituídos, composiciones farmacéuticas y métodos de uso.
BR112017026904A2 (pt) formulações farmacêuticas injetáveis de lefamulina